Teva And Bioeq Announce Commercial Partnership For FYB201; Financial Terms Not Disclosed
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets
Teva Pharmaceutical Industries Ltd. (NYSE:AND) and Bioeq AG